ConfirmMDx, a new epigenetic assay to prevent repeat biopsies
ConfirmMDx, an epigenetic assay developed by MDxHealth, uses an epigenetic field effect ("halo") to determine the risk of cancerization at a DNA level. The innovative test can help to single out men without a risk of prostate cancer from undergoing unnecessary biopsies as well as identify patients who need treatment.
Click here to watch E. David Crawford, MD, talk about his experience with MDx.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)